Form 4/A for ZNTL Zentalis Pharmaceuticals, Inc.

Accepted 2021-12-17 00:00:00 ET · period of report 2021-06-04 · accession 0001725160-21-000242 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DA	2021-12-17	2021-06-04	ZNTL	Johnson David Michael	Dir	A - Grant	$0.00	+7,500	96.4K	+8%	$0
DA	2021-12-17	2021-06-04	ZNTL	Johnson David Michael	Dir	A - Grant	$0.00	+22.5K	22.5K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-06-04	A	A	7,500	$0.00	96,355	D	—	—	(F1) This amendment is being filed to correct the number of RSUs granted to the Reporting Person, which was inadvertently understated on the Reporting Person's original Form 4. The Reporting Person was granted 7,500 RSUs on June 4, 2021, to vest on the first to occur of (a) June 4, 2022 or (b) the next occurring annual meeting of the Company's stockholders. (F2) Due to the error described above, the Reporting Person's Form 4 filed on October 4, 2021 incorrectly reported that the number of shares held by the Reporting Person was 80,959 shares of Common Stock.
2	Derivative	Stock Option (Right to Buy)	2021-06-04	A	A	22,500	$0.00	22,500	D	$52.25 · — to 2031-06-03	22,500 Common Stock	(F3) This amendment is being filed to correct the number of stock options granted to the Reporting Person, which was inadvertently understated on the Reporting Person's original Form 4. The Reporting Person was granted 22,500 options on June 4, 2021. The options vest and become exercisable in substantially equal monthly installments over the twelve (12) months following the date of grant, subject to the Reporting Person's continued service on the Board of Directors through each such vesting date.